AMI-1 sodium salt

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: AMI-1 sodium salt
• 英文别名: disodium;4-hydroxy-7-[(5-hydroxy-7-sulfonatonaphthalen-2-yl)carbamoylamino]naphthalene-2-sulfonate
• 化学式: C21H14N2Na2O9S2
• 分子量: 548.5
• InChiKey: MOUNHKKCIGVIDI-UHFFFAOYSA-L

计算性质

• 辛醇/水分配系数(LogP)：
  -3.14
• 重原子数：
  36
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  213
• 氢给体数：
  4
• 氢受体数：
  9

文献信息

• Insulin receptor activators for the treatment of metabolic disorders induced by treatment with HIV protease inhibitors
  申请人：——

  公开号：US20020061927A1

  公开（公告）日：2002-05-23

  Methods of treating a person suffering from HIV protease inhibitor-induced metabolic disorders such as lipodystrophy, hypertriglyceridemia, insulin resistance, hyperglycemia, diabetes and ketoacidosis, comprise treatment with an insulin receptor activating compound, optionally in conjunction with insulin. In general, any insulin receptor activating compound is suitable for the practice of the invention; and preferred compounds are disclosed.

  治疗HIV蛋白酶抑制剂引起的代谢紊乱，如脂肪萎缩症、高甘油三酯血症、胰岛素抵抗、高血糖、糖尿病和酮症的方法，包括使用一种胰岛素受体激活化合物进行治疗，可选地与胰岛素一起使用。一般来说，任何胰岛素受体激活化合物都适用于本发明的实施；并且优选化合物已被披露。
• Novel naphthalene ureas as glucose uptake enhancers
  申请人：——

  公开号：US20030135063A1

  公开（公告）日：2003-07-17

  Compounds of formula I are useful for treating conditions associated with hyperglycemia, especially Type II diabetes. These compounds are useful in stimulating the kinase activity of the insulin receptor, activating the insulin receptor, and stimulating the uptake of glucose. Pharmaceutical compositions comprising the antidiabetic compounds are also disclosed.

  公式I的化合物对于治疗与高血糖有关的疾病，特别是2型糖尿病非常有用。这些化合物在刺激胰岛素受体的激酶活性、激活胰岛素受体和促进葡萄糖的摄取方面非常有用。还公开了包含抗糖尿病化合物的药物组合物。
• Method for determining whether a compound is an insulin receptor kinase activator
  申请人：——

  公开号：US20020151542A1

  公开（公告）日：2002-10-17

  A method for determining whether a compound is an insulin receptor kinase activator.

  一种确定化合物是否为胰岛素受体激酶激活剂的方法。
• NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS
  申请人：Telik, Inc.

  公开号：EP1181271A2

  公开（公告）日：2002-02-27
• INSULIN RECEPTOR ACTIVATORS FOR THE TREATMENT OF METABOLIC DISORDERS IN HUMANS RESULTING FROM TREATMENT OF HIV INFECTION WITH HIV PROTEASE INHIBITORS
  申请人：TELIK, INC.

  公开号：EP1355698A2

  公开（公告）日：2003-10-29